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Abstract
The epipolythiodiketopiperazine (ETP) alkaloids are a highly complex class of natural products
with potent anticancer activity. Herein, we report the application of a flexible and scalable
synthesis, allowing the construction of dozens of ETP derivatives. The evaluation of these
compounds against cancer cell lines in culture allows for the first expansive structure–activity
relationship (SAR) to be defined for monomeric and dimeric ETP-containing natural products and
their synthetic cognates. Many ETP derivatives demonstrate potent anticancer activity across a
broad range of cancer cell lines, and kill cancer cellsviainduction of apoptosis. Several traits
thatbode well for the translational potential of the ETP class of natural products includeconcise
and efficient synthetic access, potent induction of apoptotic cell death, activity against a wide
range of cancer types, and a broad tolerance for modifications at multiple sitesthat should facilitate
small-molecule drug development, mechanistic studies, and evaluation in vivo.
Introduction
Epipolythiodiketopiperazine (ETP)1 alkaloids constitute a large (ca. 120 members) and
diverse family of biologically active secondary metabolites produced by a number of
filamentous fungi including those from the Chaetomium, Leptosphaeria, Aspergillus,
Verticillium, Penicillium, and Pithomyces genera. These small-molecule natural products
are characterized by the incorporation of an intramolecular polysulfide bridge at the α,α'-
positions of a cyclo-dipeptide (or diketopiperazine – DKP) (Fig. 1). Although mono-, di-,
tri-, and tetrasulfide members are naturally occurring, the disulfides are most prevalent.2
These mycotoxins, containing one ortwo ETP rings, exhibit a wealth of structural diversity1c
and display a fascinating spectrum of biological activities1a,3 including antibacterial,4
anticancer,3,5 antiviral,6 antiparasitic, antifungal,7 antimalarial, immunosuppressive,
immunomodulatory,1b,5a,8 phytotoxic,9nematicidal,10antiplatelet,11and anti-inflammatory
effects.1f
As a consequence of the intriguing biological activities3 and the structural diversity1cthat
surrounds the central ETP motif, access to greater quantities of the alkaloids and their
analogs is desired; a considerable number of synthetic efforts have thus been directed toward
the synthesis of the ETP core1b,12 and ETP-containing naturally occurring
alkaloids.1f,13,14Due to the synthetic challenges posed by their complex molecular
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architecture, however, structure–activity relationship (SAR) studies of ETP-containing
derivatives are still limited and warrant further exploration.1a,3Various ETP alkaloids have
been assessed in a diverse array of biological tests, but the non-uniformity of these studies
precludes comparative analysis and the inference of meaningful conclusions. As a result,
although the polysulfide warhead has been noted to be a critical pharmacophore (vide infra),
little is known about the influence of the number of sulfur atoms, the stereochemical
configuration of the sulfurated centers, or the dimerization state of the carbocyclic structure
on the bioactivity of these alkaloids. Investigation of the impact of each of these structural
features is crucial to elucidating the mode of action of these compounds, to designing highly
potentstructures with suitable physicochemical and biopharmaceutical properties, and to
their translation in vivo in clinical applications (e.g., biological probes and chemotherapeutic
agents).
Several studies have unequivocally demonstrated that the polysulfide bridge plays a key role
and is oftensufficient for bioactivity.1a–bIndeed, the chemical ablation of the sulfur bridge in
naturally occurring alkaloids (e.g., chaetocin A (4),13f gliotoxin (1)15, sporidesmin16) or the
synthesis of analogs devoid of sulfur at the α-positions of the cyclo-dipeptide17a results in
biologically inactive compounds. Similarly, reductive S-methylation of the
epidithiodiketopiperazine motif in a number of natural products (e.g., gliotoxin (1),1b,5c,n,8a
chaetocin A (4),18 scabrosin,19 sporidesmin,16,20 T988 B,21bionectin C (8),4and chetracin
D22) unfailingly results in a dramatic loss of biological activity. Furthermore, a general
pattern between the degree of sulfuration and the intensity of the biological response has not
been clearly established.1a–b,3,10,18,21–23 It is ambiguous whether these molecules go
through a common mode of action or are converted into a similar active species.
Interestingly, epimonothiodiketopiperazine metabolites have been reported to be at least one
order of magnitude less active than their congeners.1b,19,24,25
At least three pathways of toxicity have been proposed in the literature1a–c,f,5a for the ETP-
containing products: (1) generation of deleterious reactive oxygen species (ROS) (e.g.,
superoxide radical anion, hydroxyl radical, hydrogen peroxide) by redox cycling5f,k–m,26
and induction of significant oxidative stress, DNA strand cleavage, and apoptosis; (2)
covalent conjugation and inhibition of cellular proteins by forming mixed
disulfides5a,11,17,20,26b or catalytic formation of intramolecular disulfide bonds between
cysteine residues on proteins27; and (3) disruption of the global tertiary structure of proteins
containing a Zn2+-binding cysteine-histidine rich protein domain via a zinc ion ejection
mechanism.17,28
The epidithiodiketopiperazine class of natural products appears to have considerable
anticancer potential,3,5 but definitive conclusions are difficult to draw as an array of these
compounds has never been tested against a wide variety of cancer cell lines. The
verticillins5g,i,k,n and the chaetocins5d,f,h,l–m,26d,29 both exhibit cytotoxic activity against
cancer cell lines in culture and efficacy in in vivo tumor models. The true translational
potential of the ETP-containing alkaloids, however, will only be defined after a larger
number of more detailed cell culture and in vivo studies.
Recently, we reported the enantioselective total synthesis of dimeric
epidithiodiketopiperazines (+)-12,12'-dideoxyverticillin A (3) and (+)-chaetocin A (4) as
well as higher-order polysulfides (+)-chaetocin C (5) and (+)-12,12'-dideoxychetracin A (6)
relying on a bioinspired approach.14a,bSimilarly, the development of our Lewis acid-
promoted C3-nucleophilic substitution14c,30 culminated in the concise enantioselective total
synthesis of (+)-gliocladin B (7)31and (+)-12-deoxybionectin A (10).4Thesesynthetic
methodologiesoffer an opportunity to rapidly create multiple derivatives for evaluation
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against cancer cell lines in culture; many of these compounds cannot be created by simple
and direct chemical modifications of the (scarce or sensitive) parent natural mycotoxins.
With the ultimate goal of identifying ETP derivatives worthy of evaluation in vivo, and to
aid in chemotherapeutic development through potent but simplified analogs, a large set of
structurally diverse natural and synthetic ETP alkaloids were synthesized. Sixty natural
alkaloids and their derivatives (Fig. 2) were tested for their ability to induce cell death in two
human cancer cell lines, enabling the derivation of a comprehensive SAR. A selection of 25
sulfurated alkaloids with(sub)nanomolar potencies was further evaluated for activityagainst
threeadditional humancancer cell lines, allowing for a broad assessment of anticancer
effects. Representative compounds from the monomer and dimer classes were shown to
induce caspase-dependent apoptosis. The potent and broad anticancer activity of ETP-
containing alkaloids suggests that they have considerable translational potential.
Design and synthesis of ETP alkaloids
Overview of synthetic goals
Sulfur atoms have long been recognized as essential to the anticancer activity of ETP natural
products; however, a more refined understanding of structure–activity relationships has been
lacking. To identify how this and other structural elements within the
hexahydropyrroloindoline and diketopiperazine substructures are critical to the anticancer
activity, multiple derivatives of both monomeric and dimeric ETP alkaloids were
synthesized and evaluated. The general strategy for derivatives was to construct sets of
compounds that varied in the substituents about the hexahydropyrroloindolinecarboskeleton
and the nature, extent, and configuration of sulfuration. The compounds produced through
these synthetic efforts are depicted in Fig. 2.
Design and synthesis of sarcosine-derived monomeric ETP derivatives
In an effort to formulatea SAR for homodimeric tryptophan-derived ETP alkaloids such as
chaetocin A (4) and verticillin A (2), various derivatives of thisalkaloid class were
synthesized and evaluated. Specifically, compounds that were differentially substituted at
the C3-quaternary stereogenic center were constructed and then elaborated with different
types of sulfur motifs. Relying on the versatility of the different synthetic methodologies
developed in our group en route to the total synthesis of several naturally occurring
monomeric and dimeric ETP alkaloids,14 compounds 3–7, 10, and14–67 were concisely and
efficiently accessed as described in Schemes 1–3 or according to experimental procedures
previously reported by our group.14a–c,32
endo-Tetracyclic bromide 54, prepared from sarcosine L-tryptophan cyclo-dipeptide,14c was
used to access epidithiodiketopiperazines bearing different C3-substituents (Scheme 1).
Electrophilic activation using silver(I) tetrafluoroborate in nitroethane and trapping of the
transient tertiary benzylic carbocation with the desired nucleophile (i.e., fluoride, N-TIPS-
pyrrole,33 anisole, 5-Br-N-TIPS-indole) afforded the C3-substituted endo-tetracycles 59 and
68–70 in high yields and excellent levels of regio- and stereoselection.14c Dihydroxylation
of 59 and 68–70 at the C11-methine and C15-methylene positions was achieved with tetra-
n-butylammonium permanganate (n-Bu4NMnO4, 4 equiv) in dichloromethane to provide the
corresponding diols in moderate to good yields as single diastereomers. The direct double
cis-thiolation was accomplished in a single step and in good to high yields (47–80%) by
exposure of the bis-hemiaminals to trifluoroacetic acid (TFA) in hydrogen sulfide-saturated
dichloromethane solution followed by mild aerobic oxidation to access the bridgehead
disulfides as β-epimers 26, 30–33 andα-epimers 34–35.34Interestingly, the
diastereoselectivities are consistent with the steric bias imposed by the C3-substituents {β:α
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ratio= 2:1 (C3-F);4:1 (C3-Br);> 5:1 (C3-pyrrol-3'-yl); > 7:1 (C3-indol-3'-yl); > 10:1 (C3-p-
MeOPh)}.
As shown in Scheme 2, we also prepared a set of 27 compounds with a modified sulfur
motif within the DKP core using the versatile diol 56 as a strategic point of divergence.
Relying on our unified and general solution to epidi-, epitri-, and
epitetrathiodiketopiperazines14b and the innate reactivity differences between the C11 and
C15 hemiaminals, chemo- and stereoselective thiolation of diol 56 by treatment with TFA in
hydrogen sulfide-saturated dichloromethane solution at 0 °C generated the corresponding
thiohemiaminal 48 in 90% yield and in a highly diastereoselective fashion (>10:1 dr).
Masking of both alcohol and thiol groups as isobutyrates and photoinduced reductive
removal of the benzenesulfonyl group gave 51. The desired degree of sulfidation was
eventually accomplished by hydrazinolysis, chemoselective S-sulfenylation with
chloro(triphenylmethane) sulfane or disulfane followed by hafnium triflate-mediated
cyclization to afford (+)-12-deoxybionectin A (10) and its epitrithiodiketopiperazine
congener 29 in 65 and 47% yield (3-steps), respectively. A similar two-step approach was
employed to access benzenesulfonyl-protected epitri- and epitetrathiodiketopiperazines 27
and 28 in 42% and 44% yield, respectively. Ultimately, reduction of the bridgehead
disulfide with NaBH4 followed by in situ S-methylation afforded (+)-gliocladin B (7)14c,31
and bis(methylthioether) 39 in high yields.
(+)-Gliocladin C (52)31 and several C11-hydroxylated (57–58) and C11,C12-
dehydrogenated (53) intermediates were prepared following the procedures previously
reported for the synthesis ofthis atypical non-thiolated triketopiperazine.14c
Exposure of hemiaminal 56 to benzyl mercaptan and TFA in nitroethane resulted in the
formation of the corresponding bis(benzylthioether) (C15β:C15α = 5.7:1) in 80% yield
(single diastereomer, C15β). Further derivatization of the indole nitrogen with a t-
butoxycarbonyl group gave 43 in 69% yield. After masking the indole substituent of the key
ETP intermediate 26, the bridgehead disulfide was reduced with NaBH4 and S-
methoxymethylated in a single flask. Subsequent t-butoxycarbonylremoval with TFA in
dichloromethane afforded bis(thioether) 40 in 66% yield over two steps. A similar strategy
including the photoinduced reductive removal of the N1-benzenesulfonyl group provided 41
in 55% over three steps. Reduction of the sulfur bridge of ETP 24 with NaBH4 in a mixture
of THF and methanol and in situ trapping of the resulting thiolates with 2-methoxyethoxy-
methyl chloride (MEMCl) led to thioether 47 and bis(thioether) 42 in 19% and 80% yield,
respectively.
Further modifications to the sulfur bridge1b,12c,25 were accomplished by treatment of the
corresponding dithiol (obtained from NaBH4reduction of ETP 26) with 1,1'-
thiocarbonyldiimidazole (TCDI) or 1,1'-carbonyldiimidazole (CDI) to afford di- and
trithiocarbonates 36 and 37, respectively. Similarly, thioacetal 38 was accessed directly by
double alkylation using diiodomethane. Desulfurization of epidithiodiketopiperazine 26 was
realized by treatment with triethylphosphite in THF to give epimonosulfide 25 in 63%
yield.35 The sulfur atoms were also capped with the S-acetyl and S-methylsulfane functional
groupings to afford compounds that are potentially more labile under intracellular
conditions. After reduction of the sulfur bridge of epidisulfide 26, its treatment with an
excess of acetyl chloride, methanesulfenyl chloride, or dimethyldisulfide afforded
compounds 44, 45 and 46, respectively, in good yields.
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Design and synthesis of N-methylalanine-derived monomeric ETP derivatives
We were also interested in investigating the effect of a different substituent at the C15
position of monomers. With this objective in mind, we prepared monomeric ETP-containing
products derived from N-methyl-L-alanine L-tryptophan cyclo-dipeptide (Scheme 3).
Synthesis of these derivatives commenced with endo-tetracyclic bromide 73.14a Tertiary
benzylic bromide 73 also proved to be an excellent substrate for the desired regio- and
stereoselective Friedel–Crafts-type coupling14c with 5-bromo-1-triisopropylsilylindole (67%
over 2 steps) to afford C3-indolyl tetracycle 74. Allylation of the C3-tertiary benzylic halide
using allyltributylstannane under radical conditions36 followed by hydrogenation of the
terminal olefin afforded C3-n-propyl tetracycle 75. These two C3-substituted tetracyclic
monomers were subsequently subject to hydroxylation conditions using bis(pyridine)
silver(I) permanganate (Pyr2AgMnO4) in pyridine. Treatment of the resultant diols with
potassium trithiocarbonate and TFA in dichloromethane resulted in rapid formation of the
desired monomeric dithiepanethiones 64 and 66 in 63% yield as a 5:1 isomeric mixture, as
well as 65 and 67 in 52% and 17% yield, respectively.14a Finally, exposure of these
compounds to ethanolamine in acetone followed by oxidative workup using potassium
triiodide yielded the corresponding epidithiodiketopiperazine analogs 60–63.
Design and synthesis of dimeric ETP derivatives
The synthesis of the homodimeric DKP and ETP derivatives (Schemes S1 and S2†) have
been reported previously in the literature en route to the syntheses of (+)-12,12'-
dideoxyverticillin A (3)14a as well as (+)-chaetocins A (4) and C (5) and (+)-12,12'-
dideoxychetracin A (6).14b The diacetate forms of these epidi- and
epitrithiodiketopiperazines (15–16) were also synthesized and evaluated.32 In order to
explore the effects of N1-sulfonylation on their bioactivity, a variety of related derivatives
(14, 18–19, 21–23) possessing the sulfonyl group were prepared analogously.32
Anticancer activity and structure–activity relationship studies
All 60 synthesized compounds (Fig. 2) were screened for their ability to induce death in two
human cancer cell lines: U-937 (leukemic monocyte lymphoma) and HeLa (cervical cancer).
Compounds that demonstrated anticancer activity at 1 µM or below were retested in
triplicate at a range of compound concentrations to generate logistical dose-response
curvesfrom which IC50 values were derived.32These results are presented in Table 1 and
discussed below.
Carboskeleton
In both U-937 and HeLa cells, the homodimers are the most potent compounds {IC50
(U-937) ≥ 0.18 nM; IC50 (HeLa) ≥ 0.09 nM}, with the N1,N1'-benzenesulfonylated analog
(14) of (+)-12,12'-dideoxyverticillin A (3) showing the best activity {IC50 (U-937): 0.18
nM; IC50 (HeLa): 0.09 nM}. Monomeric ETP derivatives also show satisfactory activity in
both HeLa (IC50 ≥ 5.9 nM) and U-937 (IC50 ≥ 2.8 nM) human cancer cell lines. Within the
N1-benzenesulfonyl monomeric class, various aromatic substituents (indol-3'-yl 26, N-Boc-
indol-3'-yl 24, pyrrol-3'-yl 32, p-MeO-phenyl 33) are well tolerated at the C3-position and
their IC50’s are of the same order of magnitude {IC50 (U-937): 2.8–14.8 nM; IC50 (HeLa):
22–75 nM}. Although halide substitution at C3 (bromide 30, fluorides 31 and 35) results in
intermediate activity, C3-fluorinated epidithiodiketopiperazines do not follow the trend we
observe with related ETP analogs in this SAR study. It appears that the steric environment
†Electronic Supplementary Information (ESI) available: Details for all biological assays as well as experimental procedures,
spectroscopic data, and copies of 1H, 13C, and 19F NMR spectra. See DOI: 10.1039/b000000x/
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of the C3 position is crucial for biological activity: n-alkyl groups at that position (n-propyl
analogs 61 and 65) lead to substantially lower potencies than more sterically hindered
(hetero)aryl andhalide substituentsorthe C3' quaternary carbon of a second monomeric
subunit. The superior activity of the dimers over (hetero)arylated monomers further supports
the role of steric crowding at C3.
The difference in activity between the monomers and the dimers was also observed by
Numata et al. through biological evaluation (growth inhibition in murine P388 leukemia cell
line) of the leptosins, a subset of fungal metabolites including structurally diverse dimeric
and monomeric ETP natural products.23 Dimers containing two sulfur bridge groups are one
order of magnitude more potent than monomeric C3-(3'-indolyl) analogs and 2 to 3 orders of
magnitude more potent than heterodimers bearing a single sulfur bridge. This non-linear
increase of biological activity between mono- and dimeric ETP natural products has also
been observed in other families (e.g., chetracin,22 gliocladine,10leptosin,5f,23averticillin A
(2)4) hinting at the possibility of a synergistic effect. It is unclear, however, if
pharmacokinetic properties are playing a significant role.
Comparing homodimers (+)-12,12'-dideoxyverticillin A (3), (+)-chaetocin A (4), (+)-
chaetocin C (5), and (+)-12,12'-dideoxychetracin A (6) head-to-head reveals that the
chaetocin-type ETP derivatives are more potent than their non-C15-hydroxylated
counterparts {IC50 (U-937): 0.75–1.3 nM vs. 15.5 nM; IC50 (HeLa): 5.6–6.9 nM vs. 7.2
nM}. Acetylation of the 17,17'-hydroxyl groups (15–16) also results in a reduction of
potency (5.8- to 12.9-fold for U-937; 2.0- to 11.1-fold for HeLa). Additionally, methyl
substitution at C15 in monomeric alkaloids (Trp–Ala cyclo-dipeptides 60 vs. 26 and 64 vs.
36) only affects the potency of the compoundsmoderately. In general, the differencein
potency between the different types of substituents atC15 is minimal, although it is sensitive
to variations of the steric environment. This suggests that this position could be amenable to
additional modifications, especially to optimize the pharmacokinetic parameters during drug
development.
Our SAR studies also indicate that substitution at N1 and N1' with benzenesulfonyl (14) or
trifluoroacetyl (17) groups does enhance the anticancer activity of the alkaloids, although the
magnitude of this effect is variable. In the case of a benzenesulfonyl group (14), the potency
is dramatically increased {2 orders of magnitude more potent than the corresponding
secondary aniline (+)-12,12'-dideoxyverticillin A (3)}. The trifluoroacetamide at N1 and N1'
(17vs.16) plays only a minimal role in the anticancer activity, with slightly lower IC50
values (1.1-fold for U-937; 2.5-fold for HeLa) for these derivatives. For the monomeric
ETP-containing analogs, the N1-benzenesulfonyl substitution generally amplifies the
anticancer effect in U-937 cell line (epidisulfide: 26vs. 10; epitrisulfide: 27 vs. 29). The N1
group confers significantly higher chemical stability but also likely affects the
pharmacodynamic properties of these ETPs.
Influence of the nature and degree of sulfuration
While prior studies have demonstrated that having no sulfur atoms {naturally occurring (+)-
gliocladin C (52) and synthetic analogs: opened DKP (55),non-oxidized α-positions (21, 54,
59), α-hydroxylated (22–23, 56–58), α,β-unsaturated (53)} results in a complete loss of
biological activity, our studies go further and demonstrate that sulfuration at only the
tryptophan Cα-position is not sufficient for potent activity {bis(trisulfanes) (19 and 20),
C11-thioesters (50–51), C11-thioether (49), and C11-thiols (47–48)}. This clearly reinforces
the necessity of sulfur atoms at the α and α' positions and the importance of the sulfide
bridge or sulfur containing bridge for anticancer activity. This is in accordance with the
observation made by Numata in the leptosin class, where monomeric and dimeric ETP
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alkaloids are 2 to 4 orders of magnitude more potent than heterodimeric metabolites devoid
of sulfur bridge.23 Both amino acid Cα positions appear torequire sulfuration by separate
sulfur atoms, although the epimonosulfide (25) is not completely inactive.
Sulfur derivatives possessing non-labile alkyl groups {S-methylthioethers (7 and 39), S-
(methoxymethyl)thioethers (40–41), S-(2-ethoxyethoxymethyl)thioether (42 and 47), S-
benzylthioether (43)} did not display any anticancer activity (IC50> 10 µM). Remarkably,
thioacetal 38 retains moderate cytotoxic activity.Interestingly, the degree of sulfuration of
the polysulfide bridge {dimers: (+)-chaetocin A (4) vs. (+)-chaetocin C (5) vs. (+)-12,12'-
dideoxychetracin A (6) or 15vs. 16; monomers: 10 vs. 29, 26vs. 27vs. 28} has no substantial
impact on this cell death induction and the IC50 values are within the margin of error of each
other. It is ambiguous whether these molecules go through a common mode of action or are
converted into a similar active species. The different order of polysulfides may have similar
biological activity if the rate determining step for their mode of action is after the conversion
to a common active intermediate; however, if the rate determining step is the conversion of
the bridging polysulfide into this putative species, then one may expect a difference in
activity.
In addition to ETP-containing compounds, we found that several monomeric or dimeric
derivatives possessing modifications directly on the sulfur bridge serve as competent
anticancer agents; IC50 values are<10-fold less potent compared to the parents. These
include thioacetate (44), dithiocarbonate (37), trithiocarbonates (18, 36, 64), and alkyl
disulfides (45–46). The methyl disulfides would readily be converted to the thiols through
reduction or nucleophilic displacement. The data are highly suggestive of a mode of action
that involves a common intermediate. In the presence of a reducing cytoplasmic
environment combined with the presence of enzymes – hydrolases, carboxylesterases, and
lipases37 – it is reasonable to believe that the methyl disulfides, thioacetates, and
thiocarbonates play the role of prodrugs.38 They may be converted to their corresponding
epidisulfide pharmacophores,1a,26c which are potentially actively concentrated within the
cell via a glutathione-dependent uptake mechanism.39,40
Furthermore, the relative stereochemistry of the ETP system seems to be critical since
compounds with the sulfur bridge on the α-face of the DKP (34, 62–63, 66–67) are
completely inactive.
Efficacy of ETP alkaloids across multiple cancer cell lines
In order to further probe the potential of ETP alkaloids as anticancer agents, 25 derivatives,
selected among the most potentfrom the primary screening (Table 1), were tested in
cultureagainsta panel of three supplementary human cancer cell lines representing three
additional tumor histologies (H460, lung carcinoma; 786-O, renal carcinoma; MCF-7, breast
carcinoma).32As shown in Table 2, the ETPs retain similar patterns of potency across all of
the cell lines. Some compounds, such as 14, retain higher levels of activity in all of the cell
lines as compared to others, such as 17. Generally, however, U-937 and HeLa are slightly
more sensitive to the ETPs than the other three cell lines. In particular,thenon-adherent
lymphoma cell line U-937 showsthe highest susceptibility to the ETP class, as evidenced by
the generally high potency of both monomers and dimers against this cell line.
The polysulfide dimers (+)-12,12'-dideoxyverticillin A (3), (+)-chaetocins A (4) and C (5),
(+)-12,12'-dideoxychetracin A (6), 14, and bisdithiepanethione 18 are the most active
compounds across the board. In the case of the N1,N1'-benzenesulfonylated analog of
(+)-12,12'-dideoxyverticillin A (14), the potency is dramatically increased (2 orders of
magnitude more potent than the parent natural product 3 on the five tested cell lines). Our
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SAR studies show that the number of sulfur atoms in the bridge for homodimeric ETP
derivatives has no significant effect.
Some additional trends are apparent from the data derived from this extended panel of cell
lines. First, the degree of sulfuration has a larger impact in some of the adherent cell lines
tested (H460, 786-O, and MCF-7), especially in the case of 26–28. This set of compounds
shows a 2-fold decrease in activity with each additional sulfur atom in the polysulfide
bridge. However, the overall potency of these compounds is still reasonable (i.e., IC50< 300
nM). Interestingly, it appears that lack of substitution at N1 (10 and 29) mitigates this effect.
This trend is also not observed within the dimers (4–6), which is again consistent with the
lack of substitution at N1. Monomeric ETP derivativeswith weaker activity in our initial
assays (31, 60, and 64) were generally less potent in these additional cancer cell lines.
Thethree prodrugs of the epidisulfide bridge (bisthioacetate 44, trithiocarbonate 36,
dithiocarbonate 37) display lower activity than the corresponding epidisulfide 26; however,
they all showconsistently lower IC50 values than the parent epidisulfide 10 (up to 6.7-fold
more potent). There were several derivatives which displayed drastically different activity
across cell lines; C3-pyrrolyl 32 and C3-p-methoxyphenyl 33 epidisulfides displayed a
consistent potency (4-fold change in activity, as compared to 6- to 40-fold changes for
otherderivatives) in addition to good relative potency in H460 cells, especially when
compared to the activity of structurally similar derivatives.
Hemolytic activity of ETP alkaloids
Compounds that induce death in a range of diverse cancer cell lines with single-digit
nanomolar potency are valuable, and an emerging application of such compounds is as
antibody-drug conjugates (ADC).41 ADCs use a covalently-bound antibody to selectively
target a potent cytotoxin to a tumor site, as exemplified by Seattle Genetics’ brentuximab
vedotin (an ADC with monomethyl auristatin E) that was recently approved by the FDA for
the treatment of Hodgkin’s lymphoma and anaplastic large cell lymphoma.41Some of the
compounds described herein possess traits that suggest potential as ADCs, including ready
synthetic access, detailed knowledge of sites that can be modified without loss of activity,
and significant potency across a broad panel of cancer cell types. Lack of hemolytic activity
is an additional prerequisite for success in the ADC arena, as any hemolysis would be a non-
starter for an intravenous drug. Thus the 25 derivatives listed in Table 2 were evaluated for
their ability to induce hemolysis in human erythrocytes at concentrations well above their
anticancer IC50 values.As shown in Figure S332, the compounds show no hemolytic
activity. The concentrations at which hemolytic activity was assessed (1 and 10 µM) are, in
some cases,over 1000-foldhigher than the IC50 values for cancer cells, indicating significant
selectivity.
ETP alkaloids induce caspase-3 dependent apoptotic cell death
Two of the most active compounds from the monomer (26 and 33) and dimer (5 and 14)
classes were further examined for their ability to induce caspase-dependent apoptotic
pathway on U-937 cells. Apoptosis is a form of programmed cell death (type I) where
cysteine proteases (caspases) are activated and cleave a host of cellular substrates, ultimately
resulting in well-defined morphological changes in the cells leading to death. These changes
include membrane blebbing, chromatin condensation, and externalization of
phosphatidylserine in the plasma membrane.42
The induction of apoptosis was first evaluated by the level of phosphatidylserine
externalization (detected by FITC-conjugated Annexin V (AnnV)) that occurs prior to the
disruption of cell membrane integrity (detected by propidium iodide (PI)).32 The progression
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of cells through the AnnV+/PI- quadrant (lower right, Fig.3a) demonstrates the ability of
both monomeric and dimeric ETP-containing derivatives to induce apoptosis.
Another marker of apoptosis is the cleavage patterns of various intracellular proteins.
Caspase-3, one of the key apoptotic executioner caspases, is activated from its low-activity
zymogen (procaspase-3) at an early stage of apoptosis. This activation can be visualized by
Western blot (Fig. 3b) by the cleavage of procaspase-3 (35 kDa) to caspase-3 (12 and 17
kDa). Caspase-3 in turn cleaves one of its cellular substrates, PARP-1.
Treating cells with the four ETP derivatives, followed by Western blotting for procaspase-3/
caspase-3 and PARP-1 reveals that all these compounds induce cleavage of procaspase-3
and PARP-1. Combined, the data in Fig.3 indicate that these ETP derivatives induce
caspase-dependent apoptotic cell death rather than necrosis.
Conclusions
The implementation of a highly modular and generally applicable strategy for the synthesis
of ETP-containing alkaloids has enabled the compilation of 60 derivatives of this class of
natural products. This expansive collection of compounds was instrumental in the
development of a comprehensive SAR profile. These verticillin- and chaetocin-related
compounds were investigated for antitumor activity using five human cancer cell lines. Four
sites were targeted for derivatization in this study:N1, C3, C17, and C11/C15 (Fig.4).
Human cancer cell lines were most responsive to variations in functionalization at the C3
and C11/C15 centers while displaying a more modest response to modification at the N1 and
C17 positions. In particular, it was found that the compounds were highlypotent only if the
diketopiperazines were sulfurated at theC11/C15 sites in a manner consistent with a species
capable of being converted to a β-epidisulfide in the biological milieu. Furthermore, the
anticancer potencies of this collection of compounds correlate positively with the steric
environment at the C3 position, rendering the dimeric ETP alkaloids the most potent with
(sub)nanomolar IC50’s against a range of human cancer cell lines. The muted sensitivity of
these cell lines to variations in N1 and C17 substitution make these ideal sites for compound
optimization. Finally, despite their attenuated activity, the lower molecular-weight
monomers may prove to have more optimal pharmacokinetic properties and provide further
avenues for molecular modification in the optimization and development of small-molecule
drugs.
Notwithstanding the considerable attention it has gained from biologists and chemists, the
exact modes of action by which this class of compounds operates have yet to be fully
determined. Three mechanistic pathways have been extensively discussed in the
literature;1a–c,f,5ahowever, the role of these processes in toxicity is equivocal and many
findings can be contradictory.26b,43The large collection of compounds described herein will
enable a more thorough evaluation of the specific biological targets of the ETP-containing
alkaloids, and novel synthetic dimer 14, in particular, has remarkable potency. Importantly,
these compounds are efficiently prepared through concise synthetic routes that
affordsubstantial chemical and structural diversity. The implementation of this synthetic
discovery platform provides a unique opportunity to study important biological and
physiological processes, to validate biological hypotheses, and to discover very promising
small-molecules.44 Additionally, the ETPs would be excellent candidates for ADC
therapies,41 a strategy which requires highly potent compounds and selectively delivers drug
to a cellular target.
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Cell culture MTS and SRB cytotoxicity assays reveal potent and wide-ranging anticancer
activity for 25 natural and unnatural ETP derivatives in the (sub)nanomolar range against a
broad variety of cancer types and demonstrate a broad structure–activity relationship:eight
sarcosine-derived monomers and five homodimers exhibited potency in the single digit
nanomolar range, while chaetocins A (4) and C (5) as well as verticillin-related compound
14displayed subnanomolar IC50 values. In addition to their activity against cancer cells, the
ETPs are not active against human erythrocytes.These compounds are attractive candidates
for further studies investigating mode ofaction and exploring translational potential.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Representative thiodiketopiperazines.
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Fig 2.
Molecules synthesized and evaluated for anticancer activity in this study.
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Fig. 3.
ETP derivatives induce caspase-dependent apoptotic cell death.32 a) Analysis of
phosphatidylserine exposure and propidium iodide inclusion at 24 hours in U-937 cells.
Compounds were tested at 100-times their 72-hour IC50 values [14 (20 nM), 5 (75 nM), 26
(250 nM), and 33(500 nM)]. STSwas used at 50 nM as a positive control for apoptosis. b)
Western blot analysis of Pro-C3 and PARP-1 cleavage at 24 hours in U-937 cells using β-
actin as loading control. Compounds were tested as above, with the exception of STS (100
nM); C3 = caspase-3; ETP = epipolythiodiketopiperazine; FITC = fluorescein
isothiocyanate; IC50 = half maximal inhibitory concentration;PARP = poly(ADP-ribose)
polymerase 1; Pro-C3 = procaspase-3; STS = staurosporine.
Boyer et al. Page 15
Chem Sci. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Summary of ETP structure–activity relationship.
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Scheme 1.
Sarcosine-derived monomeric epidithiodiketopiperazines: modulation of the C3-substituent.
Reagents and conditions: (a) AgBF4, DTBMP, EtNO2, 23 °C, 1 h, 90%; (b) N-TIPS-pyrrole,
AgBF4, DTBMP, EtNO2, 0 °C, 1 h, 72%; (c) Anisole, AgBF4, DTBMP, EtNO2, 0 °C, 1 h,
99%; (d) 5-Br-N-TIPS-indole, AgBF4, DTBMP, EtNO2, 0 °C, 1 h; 83%; (e) H2, Pd/C, NEt3,
MeOH–EtOAc (2:3 v/v), 23 °C, 8 h; Et3N•3HF, 23 °C, 13 h, quant.; (f) n-Bu4NMnO4,
CH2Cl2, 23 °C, 2 h, 25–52%; (g) H2S, TFA–EtNO2 (2:3 v/v), 0 to 23 °C, 4 h; O2, EtOAc,
23 °C, 47–80%; TIPS = triisopropylsilyl; DTBMP = 2,6-di-tert-butyl-4-methylpyridine;
TFA = trifluoroacetic acid.
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Scheme 2.
Sarcosine-derived monomeric polythiodiketopiperazines: modulation of the sulfur bridge.
Reagents and conditions: (a) N2H4, THF, 0 °C, 1 h; Ph3CSCl, NEt3, THF, 0 °C, 90 min,
81% (2-steps); (b) N2H4, THF, 0 °C, 1 h; Ph3CSSCl, Hünig’s base, THF, 0 °C, 25 min; (c)
Hf(OTf)4, MeCN, 23 °C, 15 min, n=0: 80%, n=1: 47% (3-steps); (d) H2S, TFA–CH2Cl2
(1:9 v/v), 0 to 23 °C, 2 h, 90%, >10:1 dr; (e) Ph3CSSmCl, Hünig’s base, THF, 0 °C, 25 min;
Hf(OTf)4, MeCN, 23 °C, 50 min, m=1: 42% (2-steps), m=2: 44% (2-steps); (f) MeI, NaBH4,
Pyr, THF, MeOH, 23 °C, 45 min, 80%; (g) BnSH, TFA–EtNO2 (2:3 v/v), 23 °C, 3 h, 80%,
17:3dr; (h) Boc2O, DMAP, MeCN, 23 °C, 3 h, 69%; (i) H2S, TFA–EtNO2 (3:4 v/v), 0 to 23
°C, 2 h; O2, EtOAc, 23 °C, 77%, >7:1 dr; (j) Boc2O, DMAP, CH2Cl2, 23 °C, 7 h, 81%; (k)
NaBH4, THF, MeOH, 23 °C, 2 h; MOMCl, NEt3, 23 °C, 5 h, 73%; (l) TFA, CH2Cl2, 0 to 23
°C, 3 h, 81–91%; (m) hν (350 nm), 1,4-dimethoxynaphthalene, ascorbic acid, sodium
ascorbate, H2O–MeCN (1:4 v/v), 25 °C, 2.5 h, 82%; (n) NaBH4, THF, MeOH, 23 °C, 80
min; MEMCl, NEt3, 23 °C, 12 h, 80% (42) and 19% (47); (o) NaBH4, THF, MeOH, 23 °C,
45 min; (p) TCDI, CH2Cl2, 23 °C, 22 h, 34% (2-steps); (q) CDI, CH2Cl2, 23 °C, 24 h, 8%
(2-steps); (r) CH2I2, NaBH4, Pyr, THF, MeOH, 0 to 23 °C, 1 h, 46%; (s) P(OEt)3, THF, 23
°C, 6 h, 63%; (t) AcCl, Pyr, CH2Cl2, 23 °C, 4 h, 63% (2-steps); (u) MeSCl, Pyr, CH2Cl2, 0
to 23 °C, 2 h, 49% (2-steps); (v) (MeS)2, THF, 23 °C, 19 h, 41% (2-steps); TFA =
trifluoroacetic acid; Pyr = pyridine; Boc2O = di-tert-butyl dicarbonate; DMAP = 4-
(dimethylamino)pyridine; TCDI =1,1’-thiocarbonyldiimidazole; CDI =1,1’-
Boyer et al. Page 18
Chem Sci. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
carbonyldiimidazole;MOMCl = chloromethyl methyl ether; MEMCl = 2-
methoxyethoxymethyl chloride.
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Scheme 3.
Alanine-derived monomeric polythiodiketopiperazines: modu-lation of the C3-substituent.
Reagents and conditions: (a) 5-Br-N-TIPS-indole, AgBF4, DTBMP, EtNO2, 0 °C, 1 h, 67%;
(b) H2, Pd/C, NEt3, MeOH–EtOAc (2:3 v/v), 23 °C, 8 h; Et3N•3HF, 23 °C, 13 h, quant.; (c)
AllylSnBu3, AIBN, PhH, 80 °C, 5 h, 61%; (d) H2, Pd/C (5 mol %), CH2Cl2, 2 h, 100%; (e)
Pyr2AgMnO4, Pyr, 23 °C, 4 h, 37% (R=indol-3’-yl), 68% (R=n-Pr); (f) K2CS3, TFA–
CH2Cl2 (1:2 v/v), 23 °C, 2.5 h, 63%, 5:1 dr (64:66), 52% (65), 15% (67); (g) ethanolamine,
acetone, 23°C, 45 min; KI3, Pyr, CH2Cl2, 23°C, 48%, 5:1 dr (60:62), 70% (61), 78% (63);
TIPS = triisopropyl-silyl;DTBMP = 2,6-di-tert-butyl-4-methyl-pyridine; AIBN = α,α′-
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azoisobutyronitrile;Pyr2AgMnO4 = bis(pyridine) silver(I) permanganate; Pyr = pyridine;
TFA = trifluoroacetic acid.
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Table 1
Assessment of the 60 ETPs and DKPs from Fig. 2 for anticancer activity against U-937 (hystiocytic
lymphoma) and HeLa (cervical carcinoma) human cancer cell lines after a 72-hour exposure.a
a72-hour IC50 values (in nM) as determined by MTS (U-937) and SRB (HeLa).32 Error is standard deviation of the mean, n ≥ 3. Cmpd =
compound DKP = diketopiperazine ETP = epipolythiodiketopiperazine IC50 = half maximal inhibitory concentration MTS = 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H–tetrazolium SRB = sulforhodamine B.
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Table 2
Assessment of the top 25 compounds for cytotoxicity in five human cell lines {U-937 (hystiocytic lymphoma),
HeLa (cervical carcinoma), H460 (lung carcinoma), 786-O (renal carcinoma), and MCF-7 (breast carcinoma)}
after a 72-hour exposure.a
a72-hour IC50 values (in nM) as determined by MTS (U-937) and SRB (HeLa, H460, 786-O, and MCF-7).32 Error is standard deviation of the
mean, n ≥ 3 Cmpd = compound IC50 = half maximal inhibitory concentration MTS = 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H–tetrazolium SRB = sulforhodamine B.
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